Tech Company Financing Transactions
NMD Pharma Funding Round
NMD Pharma closed a $81.9 million Series B venture capital round on 11/16/2023. Investors included Jeito Capital, INKEF Capital and Lundbeckfonden BioCapital.
Transaction Overview
Company Name
Announced On
11/16/2023
Transaction Type
Venture Equity
Amount
$81,880,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the financing will be used to complete three Phase 2 studies with NMD670, the company's lead ClC-1 inhibitor.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
405 Waltham St. #391
Lexington, MA 02421
USA
Lexington, MA 02421
USA
Phone
Undisclosed
Website
Email Address
Overview
NMD Pharma discovers and develops novel therapeutics for neuromuscular diseases. NMD Pharma has a unique experimental platform focusing on ion channel function and electrophysiology of skeletal muscle. We develop small molecule inhibitors of skeletal muscle-specific ClC-1 ion channels that have a promising therapeutic potential in a range of neuromuscular diseases in which muscle activation is failing leading to muscle weakness and excessive fatigue that compromise the ability of patients to conduct essential human behaviour and cause lack of independence.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Thomas Pedersen
Chief Operating Officer
Thomas Petersen
Co-Founder
Ole Nielsen
Co-Founder
Claus Olesen
Browse more venture capital transactions:
Prev: 11/16/2023: Taproot Wizards venture capital transaction
Next: 11/16/2023: Artifact Lab venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs